Shares of alcohol beverage maker Constellation Brands, Inc. (NYSE: STZ) have lost 7 percent year-to-date and the steep discount versus its peers makes
it Jefferies' top large-cap growth idea.
The Analyst
Kevin Grundy maintains a Buy rating on Constellation Brands with an unchanged $283 price target.
The Thesis
Constellation Brands is scheduled to report its second-quarter results Thursday morning, which Grundy said should come in ahead
of expectations. The company likely benefited from favorable summer weather and product innovation. Third-party sales trends from
Nielsen suggests a 13.5-percent growth in the beer business, which accounts for around
70 percent of total profit.
Constellation is expected to report Q2 earnings of $2.60 per share on sales of $2.25 billion.
Investors can expect to see a downward revision to management's $9.40 to $9.70 EPS guidance for the full year due to the
$4 billion
investment in Canopy Growth Corp (NYSE: CGC), Grundy said in a note. A reasonable guide down to a new range of $9.10-$9.40 is
justified due to near-term dilution and any accretion from the deal isn't expected until fiscal 2021.
The stock's weakness since the start of the year implies shares are trading at 15 times NTM EV/EBITDA (excluding the Canopy
portion of the business), which is a discount to the 17 to 18 times recent average and its peers who trade at around 21 to 22
times.
As such, the stock is a top large-cap growth idea based on expectations for continued growth in beer through at least 2021,
exposure to the new cannabis market and an attractive valuation.
Price Action
Constellation Brands was trading flat Wednesday around $212.28 per share.
Related Links:
Constellation
Brands Is Overvalued, Susquehanna Says In Downgrade
Stifel's
5-Year Bullish Stance On Constellation Brands Fizzles
Latest Ratings for STZ
Date |
Firm |
Action |
From |
To |
Oct 2018 |
Susquehanna |
Maintains |
Negative |
Negative |
Sep 2018 |
Morgan Stanley |
Maintains |
Overweight |
Overweight |
Sep 2018 |
JP Morgan |
Maintains |
Overweight |
Overweight |
View More Analyst Ratings for
STZ
View the Latest Analyst
Ratings
© 2018 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.